An interventional study of Dexamethasone in Impacted Mandibular Third Molar and Postoperative Pain, sponsored by 28 Military Dental Centre Lahore. Active, not recruiting at 1 site in Pakistan. Open to participants aged 20 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-04-20.
Sponsored by 28 Military Dental Centre Lahore · Not applicable, Interventional, and Treatment
This randomized clinical trial aims to evaluate the effectiveness of dexamethasone injection in reducing postoperative pain after surgical removal of impacted mandibular third molars. Patients are divided into two groups: one receiving standard local anesthesia, and the other receiving an additional dexamethasone injection postoperatively. Pain levels are assessed using the Visual Analogue Scale (VAS) at 24, 48, and 72 hours after surgery. The study is conducted at 28 Military Dental Centre, Lahore.
Impacted mandibular third molar surgery is commonly associated with postoperative pain, which can affect patient comfort and recovery. Corticosteroids such as dexamethasone have anti-inflammatory properties and may reduce postoperative pain and swelling.
This randomized clinical trial is designed to compare postoperative pain levels in patients undergoing third molar surgery with and without the administration of dexamethasone. Patients are randomly allocated into two groups. Group 1 receives standard inferior alveolar nerve block using 2% lignocaine with epinephrine. Group 2 receives an additional 1 ml (8 mg) dexamethasone injection in the buccal vestibule after completion of surgery.
Pain is assessed using the Visual Analogue Scale (VAS) at 24, 48, and 72 hours postoperatively. All patients are prescribed the same postoperative analgesic regimen. The primary outcome is the difference in mean pain scores between the two groups. Data analysis is performed using SPSS, and statistical significance is set at p \< 0.05.
5,640 studies on the registry are indexed under Pain, Postoperative; 1,230 are open to participants now.
This study's enrollment of 70 is close to the median of 75 across 4,821 interventional studies indexed under Pain, Postoperative.
Browse Pain, Postoperative studies →28 Military Dental Centre Lahore is the lead sponsor of 3 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dexamethasone 8 mg (1 ml) was administered via buccal vestibular injection immediately after surgical removal of impacted mandibular third molars.
Drug: Dexamethasone
Participants will receive standard postoperative care without dexamethasone following surgical removal of impacted mandibular third molars.
Dexamethasone 8 mg (1 ml) was administered via buccal vestibular injection immediately after surgical removal of impacted mandibular third molars.
Postoperative pain intensity
Postoperative pain will be assessed using a 10-point Visual Analog Scale (VAS), where 0 indicates no pain and 10 indicates worst possible pain, following surgical removal of impacted mandibular third molars.
Time frame: 24 hours, 48 hours, and 72 hours postoperatively
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2025 (actual). Primary completion is estimated for May 2026, 5 months after the start.
Of 2,089 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 5 months is below that.
Counting every sponsor, half of 2,102 studies reached it within 11 months; a quarter within 6 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexamethasone
28 Military Dental Centre Lahore